South and Central America Metastatic Cancer Drugs Market Forecast to 2028

Report Code : BMIRE00025362 | Region : LAMEA | Industry : Pharmaceuticals | Published Date : 15/Jul/2022
South and Central America Metastatic Cancer Drugs Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Cancer Type (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, and Others), Route of Administration (Intravenous and Intramuscular), Drug Class (HER2 Inhibitors, Immune Checkpoint Inhibitors, PARP Inhibitors, Kinase Inhibitors, and Others), Product (Branded, Generics, and Biosimilars), and End User (Hospital, Specialty Clinic, and Others)

The South and Central America metastatic cancer drugs market is expected to reach US$ 5,351.77 million by 2028 from US$ 3,934.05 million in 2021; it is estimated to grow at a CAGR of 4.5% from 2021 to 2028.

Among all the observations recorded about cancer in the region over the past several decades, one statistic has remained unchanged—metastatic cancer accounts for up to 90% of all cancer deaths each year. These numbers have motivated doctors and researchers to find new ways to treat metastasis, which occurs when cancer spreads beyond its point of origin. Such rise in the prevalence of cancer and metastatic cancer is driving the growth of the metastatic cancer drug market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the metastatic cancer drugs market growth in the coming years. The market is expected to grow at a good CAGR during the forecast period.

South and Central America Metastatic Cancer Drugs Market Revenue and Forecast to 2028 (US$ Million)

South and Central America Metastatic Cancer Drugs Market Segmentation

The market for South and Central America metastatic cancer drugs market is segmented into cancer type ,route of administration ,drug class , product , and end user. Based on cancer type, the market is segmented into breast cancer, lung cancer, liver cancer, haematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Based on route of administration, the market is bifurcated into intravenous and intramuscular. Based on drug class, the South and Central America metastatic cancer drugs market is segmented into HER2 inhibitors, immune checkpoint inhibitors, parp inhibitors, kinase inhibitors, and others. Based on product, the market is segmented into branded, generics, and biosimilars. Based on end user, the market is segmented into hospital, specialty clinic, and others. By country, the South and Central America metastatic cancer drugs market is segmented into Brazil , Argentina and Rest of South and Central America .

South and Central America Metastatic Cancer Drugs Market – Companies Mentioned

AbbVie Inc. ; Amgen Inc.; Bristol-Myers Squibb Company ; F. HOFFMANN-LA ROCHE LTD. ; Novartis AG ; Astrazeneca ; MERCK KGaA ; Pfizer Inc. (Arena Pharmaceutical GmbH); and Johnson and Johnson Services, Inc.are among the leading companies in the South and Central America metastatic cancer drugs market .

The List of Companies - South and Central America Metastatic Cancer Drugs Market

● AbbVie Inc.                                                                                                          

● Amgen Inc.                                                                                                           

● Bristol-Myers Squibb Company                                                                   

● F. HOFFMANN-LA ROCHE LTD.                                                                   

● Novartis AG                                                                                                       

● Astrazeneca                                                                                                      

● MERCK KGaA                                                                                                    

● Pfizer Inc. (Arena Pharmaceutical GmbH)                                             

● Johnson and Johnson Services, Inc.

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 South and Central America Metastatic Cancer Drugs Market – By Cancer Type

1.3.2 South and Central America Metastatic Cancer Drugs Market – By Route of Administration

1.3.3 South and Central America Metastatic Cancer Drugs Market – By Drug Class

1.3.4 South and Central America Metastatic Cancer Drugs Market – By Product

1.3.5 South and Central America Metastatic Cancer Drugs Market – By End User

1.3.6 South and Central America Metastatic Cancer Drugs Market – By Country

2. South and Central America Metastatic Cancer Drugs Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. South and Central America Metastatic Cancer Drugs Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 South & Central America– PEST Analysis

4.3 Expert Opinion

5. South and Central America Metastatic Cancer Drugs Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 High Prevalence of Metastatic Cancer

5.1.2 Government Initiatives to Support Developments in Cancer Treatment

5.2 Market Restraints

5.2.1 High Cost of Oncology Drugs

5.3 Market Opportunities

5.3.1 Investments in Artificial Intelligence for Oncology Drug Development

5.4 Future Trends

5.4.1 Increase in Launch of Metastatic Cancer Drugs

5.5 Impact analysis

6. South and Central America Metastatic Cancer Drugs Market – Country Analysis

6.1 South and Central America Metastatic Cancer Drugs Market Revenue Forecast and Analysis

6.1.1 South and Central America Metastatic Cancer Drugs Market, By Country - Forecast and Analysis to 2028 (USD Million)

7. South and Central America Metastatic Cancer Drug Market Analysis – By Cancer Type

7.1 Overview

7.2 South and Central America Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)

7.2.1 South and Central America: South and Central America Metastatic Cancer Drug Market, by Cancer Type, 2019–2028 (USD Million)

7.3 Breast Cancer

7.3.1 Overview

7.3.2 Breast Cancer: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Lung Cancer

7.4.1 Overview

7.4.2 Lung Cancer: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.5 Liver Cancer

7.5.1 Overview

7.5.2 Liver Cancer: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.6 Hematological Cancer

7.6.1 Overview

7.6.2 Hematological Cancer: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.7 Brain Cancer

7.7.1 Overview

7.7.2 Brain Cancer: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.8 Prostate Cancer

7.8.1 Overview

7.8.2 Prostate Cancer: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.9 Pancreatic Cancer

7.9.1 Overview

7.9.2 Pancreatic Cancer: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.10 Others

7.10.1 Overview

7.10.2 Others: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8. South and Central America Metastatic Cancer Drug Market – By Route of Administration

8.1 Overview

8.2 South and Central America Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)

8.2.1 South and Central America: South and Central America Metastatic Cancer Drug Market, by Route of Administration, 2019–2028 (USD Million)

8.3 Intravenous

8.3.1 Overview

8.3.2 Intravenous: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Intramuscular

8.4.1 Overview

8.4.2 Intramuscular: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Oral

8.5.1 Overview

8.5.2 Oral: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.6 Others

8.6.1 Overview

8.6.2 Others: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9. South and Central America Metastatic Cancer Drug Market – By Drug Class

9.1 Overview

9.2 South and Central America Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)

9.2.1 South and Central America: South and Central America Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

9.3 HER2 Inhibitors

9.3.1 Overview

9.3.2 HER2 Inhibitors: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Immune Checkpoints Inhibitors

9.4.1 Overview

9.4.2 Immune Checkpoints Inhibitors: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.5 PARP Inhibitors

9.5.1 Overview

9.5.2 PARP Inhibitors: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.6 Kinase Inhibitors

9.6.1 Overview

9.6.2 Kinase Inhibitors: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.7 Others

9.7.1 Overview

9.7.2 Others: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

10. South and Central America Metastatic Cancer Drug Market – By Product

10.1 Overview

10.2 South and Central America Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)

10.2.1 South and Central America: South and Central America Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

10.3 Branded

10.3.1 Overview

10.3.2 Branded: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

10.4 Generics and Biosimilars

10.4.1 Overview

10.4.2 Generics and Biosimilars: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11. South and Central America Metastatic Cancer Drug Market – By End User

11.1 Overview

11.2 South and Central America Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)

11.2.1 South and Central America: South and Central America Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

11.3 Hospital

11.3.1 Overview

11.3.2 Hospitals: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11.4 Specialty Clinic

11.4.1 Overview

11.4.2 Specialty Clinics: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11.5 Others

11.5.1 Overview

11.5.2 Others: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

12. South and Central America Metastatic Cancer Drugs Market – Regional Analysis

12.1 South and Central America: South and Central America Metastatic Cancer Drugs Market

12.1.1 Overview

12.1.2 South and Central America: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.3 South and Central America: South and Central America Metastatic Cancer Drug Market, by Country, 2021 & 2028 (%)

12.1.3.1 Brazil: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.3.1.1 Brazil: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.3.1.2 Brazil: South and Central America Metastatic Cancer Drug Market, by Cancer Type, 2019–2028 (USD Million)

12.1.3.1.3 Brazil: South and Central America Metastatic Cancer Drug Market, by Route of Administration, 2019–2028 (USD Million)

12.1.3.1.4 Brazil: South and Central America Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.1.3.1.5 Brazil: South and Central America Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.1.3.1.6 Brazil: South and Central America Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.1.3.2 Argentina: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.3.2.1 Argentina: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.3.2.2 Argentina: South and Central America Metastatic Cancer Drug Market, by Cancer Type, 2019–2028 (USD Million)

12.1.3.2.3 Argentina: South and Central America Metastatic Cancer Drug Market, by Route of Administration, 2019–2028 (USD Million)

12.1.3.2.4 Argentina: South and Central America Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.1.3.2.5 Argentina: South and Central America Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.1.3.2.6 Argentina: South and Central America Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.1.3.3 Rest of South and Central America: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.3.3.1 Rest of South and Central America: South and Central America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.3.3.2 Rest of South and Central America: South and Central America Metastatic Cancer Drug Market, by Cancer Type, 2019–2028 (USD Million)

12.1.3.3.3 Rest of South and Central America: South and Central America Metastatic Cancer Drug Market, by Route of Administration, 2019–2028 (USD Million)

12.1.3.3.4 Rest of South and Central America: South and Central America Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.1.3.3.5 Rest of South and Central America: South and Central America Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.1.3.3.6 Rest of South and Central America: South and Central America Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

13. South and Central America Metastatic Cancer Drug Market –Industry Landscape

13.1 Overview

13.2 Growth Strategies in the South and Central America Metastatic Cancer Drug Market, 2021-2028

13.3 Inorganic Developments

13.3.1 Overview

13.4 Organic Growth Strategies

13.4.1 Overview

14. Company Profiles

14.1 AbbVie Inc.

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 Amgen Inc.

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 Bristol-Myers Squibb Company

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 F. HOFFMANN-LA ROCHE LTD.

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 Novartis AG

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Products and Services

14.5.4 Financial Overview

14.5.5 SWOT Analysis

14.5.6 Key Developments

14.6 Astrazeneca

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Products and Services

14.6.4 Financial Overview

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 MERCK KGaA

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Products and Services

14.7.4 Financial Overview

14.7.5 SWOT Analysis

14.7.6 Key Developments

14.8 Pfizer Inc. (Arena Pharmaceutical GmbH)

14.8.1 Key Facts

14.8.2 Business Description

14.8.3 Products and Services

14.8.4 Financial Overview

14.8.5 SWOT Analysis

14.8.6 Key Developments

14.9 Johnson and Johnson Services, Inc.

14.9.1 Key Facts

14.9.2 Business Description

14.9.3 Products and Services

14.9.4 Financial Overview

14.9.5 SWOT Analysis

14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners

15.2 Glossary of Terms

LIST OF TABLES.

Table 1. South and Central America: South and Central America Metastatic Cancer Drug Market, by Country – Revenue and Forecast to 2028 (USD Million)

Table 2. South and Central America: South and Central America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 3. South and Central America: South and Central America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 4. South and Central America: South and Central America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 5. South and Central America: South and Central America Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 6. South and Central America: South and Central America Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 7. Brazil: South and Central America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 8. Brazil: South and Central America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 9. Brazil: South and Central America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 10.   Brazil: South and Central America Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 11.   Brazil: South and Central America Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 12.   Argentina: South and Central America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 13.   Argentina: South and Central America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 14.   Argentina: South and Central America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 15.   Argentina: South and Central America Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 16.   Argentina: South and Central America Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 17.   Rest of South and Central America: South and Central America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 18.   Rest of South and Central America: South and Central America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 19.   Rest of South and Central America: South and Central America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 20.   Rest of South and Central America: South and Central America Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 21.   Rest of South and Central America: South and Central America Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 22.   Recent Inorganic Growth Strategies in the South and Central America Metastatic Cancer Drug Market

Table 23.   Recent Organic Growth Strategies in the South and Central America Metastatic Cancer Drug Market

Table 24.   Glossary of Terms, South and Central America Metastatic Cancer Drugs Market

The List of Companies - South and Central America Metastatic Cancer Drugs Market

● AbbVie Inc.                                                                                                          

● Amgen Inc.                                                                                                           

● Bristol-Myers Squibb Company                                                                   

● F. HOFFMANN-LA ROCHE LTD.                                                                   

● Novartis AG                                                                                                       

● Astrazeneca                                                                                                      

● MERCK KGaA                                                                                                    

● Pfizer Inc. (Arena Pharmaceutical GmbH)                                             

● Johnson and Johnson Services, Inc.

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South and Central America Metastatic Cancer Drugs Market.

● Highlights key business priorities in order to assist companies to realign their business strategies.

● The key findings and recommendations highlight crucial progressive industry trends in South and Central America Metastatic Cancer Drugs Market, thereby allowing players across the value chain to develop effective long-term strategies.

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

● Scrutinize in-depth South and Central America market trends and outlook coupled with the factors driving the market, as well as those hindering it.

● Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(South and Central America Metastatic Cancer Drugs Market Forecast to 2028 )
  • Single User Price $3,000$2,400
  • Site Price $4,000$3,200
  • Enterprise Price $5,000$4,000
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry